BIOCON LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 304 INR | +1.79% |
|
-0.39% | +21.77% |
Presenter SpeechAishwarya Sitharam (Executives)Good morning, everyone. I'm Aishwarya Sitharam....
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Biocon Limited is an India-based biopharmaceutical company, which focuses on treating diabetes, cancer and autoimmune diseases. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. It has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as Generic Formulations in the United Sates, Europe and key emerging markets. Its API portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology and other key products. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. It has over five facilities across Bangalore, Hyderabad and Visakhapatnam in India. Its API manufacturing facilities leverage complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.
Calendar
2024-05-15
- Q4 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
298.6
INR
Average target price
279.1
INR
Spread / Average Target
-6.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +21.77% | 4.27B | |
| +2.97% | 108B | |
| +10.21% | 104B | |
| +2.47% | 22.33B | |
| -12.77% | 22.19B | |
| -7.05% | 18.69B | |
| -38.36% | 17.74B | |
| -6.50% | 17.64B | |
| +6.00% | 14.05B | |
| +37.20% | 12.51B |
- Stock Market
- Equities
- BIOCON Stock
- News Biocon Limited
- Transcript : Biocon Limited, Q2 2022 Earnings Call, Oct 22, 2021